CD19‐targeted CAR‐T cells have been significantly successful in treating refractory anti‐SRP necrotizing myopathy, severe myositis, and systemic sclerosis, achieving sustained B‐cell depletion and significant clinical remission [99]. Here, CD19 is linked to systemic sclerosis.